Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

A Phase II of Combination Daunorubicin and Cytarabine (Ara-C) and Nilotinib (TASIGNA) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression: Final Results

Aref Al-Kali, MD, Raoul Tibes, MD PhD, Jeanne Palmer, MD, Hassan B. Alkhateeb, MD, Mrinal M. Patnaik, MD MBBS, Kebede H. Begna, MD, Naseema Gangat, MBBS, Pamela Atherton, Shujun Liu, PhD, Rong He, MD, Shahrukh K. Hashmi, MD MPH, Mark R. Litzow, MD

Blood (2018) 132 (Supplement 1): 1443.

https://doi.org/10.1182/blood-2018-99-118552

Published: 2018

Journal Articles

A Phase II of Combination D aunorubicin and Cytarabine ( A ra-c) and Nilotinib ( TA signa) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression: Interim Results

Aref Al-Kali, MD, Raoul Tibes, MD PhD, Jeanne Palmer, MD, Hassan B Alkhateeb, MD, Pamela Atherton, Fei Yan, Shujun Liu, PhD, Rong He, MD, Shahrukh K. Hashmi, MD, Mark R Litzow, MD

Blood (2015) 126 (23): 3808.

https://doi.org/10.1182/blood.V126.23.3808.3808

Published: 2015

Journal Articles

AML1/ETO Cooperates with HIF1α to Promote Leukemogenesis through DNMT3a Transactivation

Xiaoning Gao, Fei Yan, PhD, Ji Lin, Li Gao, Xiaolin Lu, Shengcai Wei, Na Shen, Jiuxia Pang, Qiaoyang Ning, Ailing Deng, Yihan Xu, Jinlong Shi, Yonghui Li, Shujun Liu, PhD, Li Yu

Blood (2014) 124 (21): 3543.

https://doi.org/10.1182/blood.V124.21.3543.3543

Published: 2014

Journal Articles

Phase 1 Trial of Decitabine and Bortezomib in High Risk Acute Myeloid Leukemia (AML)

William Blum, MD, Rebecca B. Klisovic, MD, Ramiro Garzon, MD, Alison Walker, MD, Sebastian Schwind, MD, Shujun Liu, PhD, Larry Schaaf, PhD, Celia Garr, RN, Steven M. Devine, MD, Michael R. Grever, MD, John C. Byrd, MD, Guido Marcucci, MD

Blood (2010) 116 (21): 3293.

https://doi.org/10.1182/blood.V116.21.3293.3293

Published: 2010

Journal Articles

Epigenetic Targeting Via Transcriptional Inhibition of DNA Methyltransferase: a Phase I Study of Bortezomib in Combination with 5-Azacytidine in Adults with Relapsed or Refractory Acute Myeloid Leukemia (AML).

William Blum, MD, Rebecca B. Klisovic, MD, Alison Walker, MD, Ramiro Garzon, MD, Shujun Liu, PhD, Larry J. Schaaf, PhD, Kristina Humphries, Michael R. Grever, Steven M. Devine, MD, John C. Byrd, Guido Marcucci, MD,

Blood (2009) 114 (22): 2065.

https://doi.org/10.1182/blood.V114.22.2065.2065

Published: 2009

Journal Articles

MicroRNA-181a Targets TEL/AML1 Expression and Impairs Cell Proliferation in t(12;21) Acute Lymphocytic Leukemia (ALL) Cells.

Christopher Hickey, Sebastian Schwind, MD, Heiko Becker, MD, Houda Alachkar, Ramiro Garzon, MD, Yue-Zhong Wu, MS, Shujun Liu, PhD, Danilo Perrotti, MD, PhD, Guido Marcucci, MD

Blood (2009) 114 (22): 766.

https://doi.org/10.1182/blood.V114.22.766.766

Published: 2009

Journal Articles

Suppression of RISC-Independent Decoy and RISC-Mediated mRNA Base-Pairing Activities of MicroRNA-328 Is Required for Differentiation-Arrest and Enhanced Survival of Blast Crisis CML Progenitors.

Blood (2009) 114 (22): 855.

https://doi.org/10.1182/blood.V114.22.855.855

Published: 2009

Journal Articles

Evidence of MicroRNA-29b and Sp1/NFκB-HDAC Regulatory Network for KIT Expression in KIT-Driven Acute Myeloid Leukemia (AML): Biologic and Therapeutic Implications.

Shujun Liu, PhD, Lai Chu Wu, PhD, Jiuxia Pang, BS, Ramasamy Santhanam, PhD, Sebastian Schwind, MD, Yue-Zhong Wu, MS, Christopher Hickey, MS, Jianhua Yu, PhD, Anjali Mishra, PhD, Heiko Becker, MD, Chenglong Li, PhD, Roger Briesewitz, PhD, Robert A. Baiocchi, MD, Kenneth K. Chan, PhD, Michael A. Caligiuri, MD, John C. Byrd, MD, Danilo Perrotti, MD, PhD, Ramiro Garzon, MD, Guido Marcucci, MD

Blood (2009) 114 (22): 938.

https://doi.org/10.1182/blood.V114.22.938.938

Published: 2009

Journal Articles

Phase I Study of Lenalidomide in Acute Leukemia: Remissions in Post-Allogeneic Relapse of Acute Myeloid Leukemia.

Jason C. Chandler, MD, Rebecca B. Klisovic, MD, Mitch A. Phelps, PhD, Alison Walker, MD, Ramiro Garzon, MD, Xiaoxia Yang, Larry Schaaf, PhD, Sebastian Schwind, MD, Heiko Becker, MD, Shujun Liu, PhD, Chris Hickey, Cheryl Kefauver, RN, Jon Mickle, CNP, Steven M Devine, MD, Michael R. Grever, MD, John C. Byrd, MD, Guido Marcucci, MD, William Blum, MD

Blood (2009) 114 (22): 841.

https://doi.org/10.1182/blood.V114.22.841.841

Published: 2009

Journal Articles

Preliminary Results of a Phase II Study of Low Dose Decitabine as a Single Agent in Older Patients (age≥60) with Previously Untreated Acute Myeloid Leukemia (AML)

William Blum, MD, Rebecca Klisovic, MD, Shujun Liu, PhD, Ramiro Garzon, MD, Cheryl Kefauver, RN, Zhongfa Liu, PhD, Jon Mickle, CNP, Hollie Devine, CNP, Steve Devine, MD, Michael R Grever, MD, Kenneth K Chan, PhD, Miguel Villalona-Calero, MD, John C. Byrd, MD, Guido Marcucci, MD

Blood (2008) 112 (11): 2957.

https://doi.org/10.1182/blood.V112.11.2957.2957

Published: 2008

Journal Articles

Final Results of a Dose Escalation Study of Flavopiridol in Acute Leukemias Using a Novel Treatment Schedule.

William Blum, MD, Rebecca B. Klisovic, MD, Amy Johnson, PhD, Cheryl Kefauver, RN, Mitch Phelps, PhD, David Lucas, PhD, Lenguyen Huynh, Shujun Liu, PhD, James T. Dalton, PhD, Michael R. Grever, MD, Guido Marcucci, MD, John C. Byrd, MD

Blood (2007) 110 (11): 890.

https://doi.org/10.1182/blood.V110.11.890.890

Published: 2007

Journal Articles

Characterization of HDACI OSU42 as a Novel Histone Deacetylase Inhibitor in AML Cell Lines.

Jin Sun, PhD, Shujun Liu, PhD, Jianhua Yu, PhD, Min Wei, BS, Charlene Mao, PhD, Haiming Ding, PhD, Jessica Kearney, BS, LeNguyen Huynh, MS, Peter Paschka, MD, Dachun Wang, PhD, Rebecca B. Klisovic, MD, Danilo Perrotti, PhD, Ching-shih Chen, PhD, Williom George Blum, MD, Guido Marcucci, MD

Blood (2006) 108 (11): 1988.

https://doi.org/10.1182/blood.V108.11.1988.1988

Published: 2006

Journal Articles

Bortezomib-Induced Down-Regulation of KIT Is Mediated by Inhibition of Sp1 and NF- k B in AML1/ETO-Positive Cells.

Shujun Liu, PhD, Jiuxia Pang, Jianhua Yu, Ph.D., Zhongfa Liu, Ph.D., Lenguyen Huynh, Jessica Kearney, Peter Paschka, M.D., Rebecca B. Klisovic, M.D., Robert Baiocchi, M.D., William Blum, M.D., Danilo Perrotti, Ph.D., Guido Marcucci, M.D.

Blood (2006) 108 (11): 4211.

https://doi.org/10.1182/blood.V108.11.4211.4211

Published: 2006

Journal Articles

In Vitro and In Vivo Evidence That TSC-22 Is a Putative Tumor Suppressor Gene in Primary Murine and Human Leukemia.

Jianhua Yu, PhD, Li Yu, PhD, Bjoern Hackanson, MD, Min Wei, BS, Zachary Boyd, BS, Akihiko Yokohama, PhD, Chunhui Liu, BS, Rossana Trotta, PhD, Hsiaoyin C. Mao, MS, Brian Becknell, PhD, Michael S. Jaung, Shujun Liu, PhD, John C. Byrd, MD, Guido Marcucci, MD, Christoph Plass, PhD, Michael A. Caligiuri, MD

Blood (2006) 108 (11): 2211.

https://doi.org/10.1182/blood.V108.11.2211.2211

Published: 2006

Journal Articles

Phase I Study of Low Dose Decitabine in Patients with Acute Myeloid Leukemia (AML): Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity.

William Blum, MD, Rebecca Bruner-Klisovic, MD, Shujun Liu, PhD, John C. Byrd, MD, Zhongfa Liu, PhD, Kenneth K. Chan, PhD, Cheryl Kefauver, R.N., Lenguyen Huynh, Michael R. Grever, MD, Guido Marcucci, MD

Blood (2005) 106 (11): 1861.

https://doi.org/10.1182/blood.V106.11.1861.1861

Published: 2005

NARROW

A Phase II of Combination Daunorubicin and Cytarabine (Ara-C) and Nilotinib (TASIGNA) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression: Final Results

A Phase II of Combination D aunorubicin and Cytarabine ( A ra-c) and Nilotinib ( TA signa) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression: Interim Results

AML1/ETO Cooperates with HIF1α to Promote Leukemogenesis through DNMT3a Transactivation

Phase 1 Trial of Decitabine and Bortezomib in High Risk Acute Myeloid Leukemia (AML)

Epigenetic Targeting Via Transcriptional Inhibition of DNA Methyltransferase: a Phase I Study of Bortezomib in Combination with 5-Azacytidine in Adults with Relapsed or Refractory Acute Myeloid Leukemia (AML).

MicroRNA-181a Targets TEL/AML1 Expression and Impairs Cell Proliferation in t(12;21) Acute Lymphocytic Leukemia (ALL) Cells.

Suppression of RISC-Independent Decoy and RISC-Mediated mRNA Base-Pairing Activities of MicroRNA-328 Is Required for Differentiation-Arrest and Enhanced Survival of Blast Crisis CML Progenitors.

Evidence of MicroRNA-29b and Sp1/NFκB-HDAC Regulatory Network for KIT Expression in KIT-Driven Acute Myeloid Leukemia (AML): Biologic and Therapeutic Implications.

Phase I Study of Lenalidomide in Acute Leukemia: Remissions in Post-Allogeneic Relapse of Acute Myeloid Leukemia.

Preliminary Results of a Phase II Study of Low Dose Decitabine as a Single Agent in Older Patients (age≥60) with Previously Untreated Acute Myeloid Leukemia (AML)

Final Results of a Dose Escalation Study of Flavopiridol in Acute Leukemias Using a Novel Treatment Schedule.

Characterization of HDACI OSU42 as a Novel Histone Deacetylase Inhibitor in AML Cell Lines.

Bortezomib-Induced Down-Regulation of KIT Is Mediated by Inhibition of Sp1 and NF- k B in AML1/ETO-Positive Cells.

In Vitro and In Vivo Evidence That TSC-22 Is a Putative Tumor Suppressor Gene in Primary Murine and Human Leukemia.

Phase I Study of Low Dose Decitabine in Patients with Acute Myeloid Leukemia (AML): Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only